Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Eaton Corporation plc (ETN) Price & Performance

ADMA Biologics Inc
Eaton Corporation plc

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs Eaton Corporation plc — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Eaton Corporation plc trades at $399.21 (market cap $153.64B). The key difference: Eaton Corporation plc is far larger — about 72.1× ADMA Biologics Inc's market cap, and Eaton Corporation plc pays a 1.11% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAETN
Market Cap
$2.13B$153.64B
Sector
HealthTechnology
52-Week High
$20.38$435.78
52-Week Low
$7.60$315.82
Enterprise Value
$2.20B$174.72B
Dividend Yield
1.11%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Eaton Corporation plc

Eaton (ETN) trades at $413.42, up 3.74% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 20.87% ROE and 13.99% net margin, though valuation ratios like a 40.45 P/E are elevated. Recent news highlights sustainability investments and AI infrastructure opportunities, while analyst consensus remains strongly positive with a $449.50 price target.

Outlook is supported by earnings momentum and sector tailwinds, but high valuation and competitive pressures pose risks. The absence of sell ratings and institutional bullishness suggest upside potential, though investors should weigh growth against premium multiples in a volatile market environment.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Eaton Corporation plc

Eaton is a global power management company providing energy-efficient solutions for electrical, aerospace, and industrial sectors. It focuses on improving sustainability through intelligent power technology.

Read more on ETN